 <h1>Brivaracetam Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of brivaracetam include:</b> acute psychosis, balance impairment, dizziness, drowsiness, fatigue, sedated state, abnormal behavior, abnormal gait, aggressive behavior, agitation, anxiety, apathy, asthenia, ataxia, depressed mood, depression, hallucination, hypersomnia, lacrimation, lethargy, nervousness, nystagmus disorder, paranoid ideation, psychomotor agitation, vertigo, irritability, emotional lability, malaise, and restlessness.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to brivaracetam: oral solution, oral tablet</i></p><p>Other dosage forms:</p><ul><li>intravenous solution</li></ul><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, brivaracetam may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking brivaracetam:</p><p>
<i>More common</i>
</p><ul>
<li>Anxiety</li>
<li>changes in behavior</li>
<li>chest pain or discomfort</li>
<li>deep or fast breathing with dizziness</li>
<li>dizziness or lightheadedness</li>
<li>double vision</li>
<li>drowsiness</li>
<li>dry mouth</li>
<li>general feeling of discomfort or illness</li>
<li>irregular heartbeat</li>
<li>irritability</li>
<li>nausea</li>
<li>numbness of feet, hands and around mouth</li>
<li>restlessness</li>
<li>seeing double</li>
<li>sensation of spinning</li>
<li>sleepiness or unusual drowsiness</li>
<li>thoughts of killing oneself</li>
<li>trouble sleeping</li>
<li>unusual drowsiness, dullness, tiredness, weakness, or feeling of sluggishness</li>
<li>unusually deep sleep</li>
<li>unusually long duration of sleep</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Shakiness and unsteady walk</li>
<li>uncontrolled eye movements</li>
<li>unsteadiness, trembling, or other problems with muscle control or coordination</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Cough</li>
<li>difficulty breathing or swallowing</li>
<li>fever</li>
<li>hives</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals</li>
<li>noisy breathing</li>
<li>reddening of the skin, especially around the ears</li>
<li>swelling of the eyes, face, or inside of the nose</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of brivaracetam may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Difficulty having a bowel movement</li>
<li>vomiting</li>
</ul><p>
<div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to brivaracetam: intravenous solution, oral liquid, oral tablet</i></p><h3>General</h3><p>The more commonly reported adverse events have included somnolence/sedation, dizziness, fatigue, and nausea/vomiting.</p><h3>Nervous system</h3><p>This drug causes dose-dependent increases in somnolence and fatigue-related adverse reactions (i.e., fatigue, asthenia, malaise, hypersomnia, sedation, and lethargy).  In clinical trials, somnolence and fatigue-related adverse reactions were reported in 25%, 20%, 26%, and 27% of patients receiving at least 50 mg/day, 50 mg/day, 100 mg/day, and 200 mg/day, respectively.  Adverse reactions related to dizziness, gait and coordination disturbances including vertigo, ataxia, nystagmus occurred in 16% of patients.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Somnolence/sedation (up to 27%), dizziness and disturbances in gait and coordination (up to 16%); fatigue-related adverse reactions (i.e., fatigue, asthenia, malaise, hypersomnia, sedation, and lethargy) </p>
<p><b>Common</b> (1% to 10%): Cerebellar coordination and balance disturbances, convulsion, vertigo<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression, anxiety, insomnia, irritability</p>
<p><b>Uncommon</b> (0.1% to 1%): Suicidal ideation, psychotic disorder, aggression, agitation<sup>[Ref]</sup></p><p>Psychiatric adverse events have been commonly reported.  During clinical trials, approximately 13% of patients (compared to 8% on placebo) reported psychiatric events which included irritability, anxiety, nervousness, aggression, belligerence, anger, agitation, restlessness, depression, depressed mood, tearfulness, apathy, altered mood, mood swings, affect lability, psychomotor hyperactivity, abnormal behavior, adjustment disorder, psychotic disorder, hallucinations, paranoia, acute psychosis and psychotic behavior.  A total of 1.7% of adult patients discontinued treatment because of psychiatric reactions (compared to 1.3% of placebo).  In pediatric trials, psychiatric events were generally similar.<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Infusion site pain</p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Hypersensitivity, bronchospasm, angioedema</p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Decreased appetite, decreased weight<sup>[Ref]</sup></p><h3>Hematologic</h3><p>In clinical trials, at least 1.8% of patients had at least 1 clinically significant decreased WBC (compared to 1.1% of placebo).<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Decreased WBC</p>
<p><b>Uncommon</b> (0.1% to 1%): Neutropenia<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea, vomiting, constipation<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Upper respiratory tract infections, cough<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Influenza<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Briviact (brivaracetam)." UCB Pharma Inc, Smyrna, GA. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p></div>
<div class="more-resources" id="moreResources">
<h2>More about brivaracetam</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>29 Reviews</li>
<li>Drug class: pyrrolidine anticonvulsants</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Brivaracetam &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
<li>Brivaracetam Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Briviact</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Seizures</li>
<li>Epilepsy</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to brivaracetam: intravenous solution, oral liquid, oral tablet</i></p><h3>General</h3><p>The more commonly reported adverse events have included somnolence/sedation, dizziness, fatigue, and nausea/vomiting.</p><h3>Nervous system</h3><p>This drug causes dose-dependent increases in somnolence and fatigue-related adverse reactions (i.e., fatigue, asthenia, malaise, hypersomnia, sedation, and lethargy).  In clinical trials, somnolence and fatigue-related adverse reactions were reported in 25%, 20%, 26%, and 27% of patients receiving at least 50 mg/day, 50 mg/day, 100 mg/day, and 200 mg/day, respectively.  Adverse reactions related to dizziness, gait and coordination disturbances including vertigo, ataxia, nystagmus occurred in 16% of patients.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Somnolence/sedation (up to 27%), dizziness and disturbances in gait and coordination (up to 16%); fatigue-related adverse reactions (i.e., fatigue, asthenia, malaise, hypersomnia, sedation, and lethargy) </p><p><b>Common</b> (1% to 10%): Cerebellar coordination and balance disturbances, convulsion, vertigo<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression, anxiety, insomnia, irritability</p><p><b>Uncommon</b> (0.1% to 1%): Suicidal ideation, psychotic disorder, aggression, agitation<sup>[Ref]</sup></p><p>Psychiatric adverse events have been commonly reported.  During clinical trials, approximately 13% of patients (compared to 8% on placebo) reported psychiatric events which included irritability, anxiety, nervousness, aggression, belligerence, anger, agitation, restlessness, depression, depressed mood, tearfulness, apathy, altered mood, mood swings, affect lability, psychomotor hyperactivity, abnormal behavior, adjustment disorder, psychotic disorder, hallucinations, paranoia, acute psychosis and psychotic behavior.  A total of 1.7% of adult patients discontinued treatment because of psychiatric reactions (compared to 1.3% of placebo).  In pediatric trials, psychiatric events were generally similar.<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Infusion site pain</p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Hypersensitivity, bronchospasm, angioedema</p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Decreased appetite, decreased weight<sup>[Ref]</sup></p><h3>Hematologic</h3><p>In clinical trials, at least 1.8% of patients had at least 1 clinically significant decreased WBC (compared to 1.1% of placebo).<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Decreased WBC</p><p><b>Uncommon</b> (0.1% to 1%): Neutropenia<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea, vomiting, constipation<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Upper respiratory tract infections, cough<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Influenza<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Briviact (brivaracetam)." UCB Pharma Inc, Smyrna, GA. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><h2>More about brivaracetam</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>29 Reviews</li>
<li>Drug class: pyrrolidine anticonvulsants</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Brivaracetam &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
<li>Brivaracetam Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Seizures</li>
<li>Epilepsy</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>